Previous 10 | Next 10 |
Gainers: Agile Therapeutics (AGRX) +81%. Kezar Life Sciences (KZR) +75%. Decibel Therapeutics (DBTX) +21%. Sutro Biopharma (STRO) +16%. Bellerophon Therapeutics (BLPH) +11%. Losers: Scholar Rock (SRRK) -11%. NGM Biopharmaceuticals (NGM)...
NEW YORK, June 28, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: Kezar Life Sciences (NASDAQ: KZR), Nova Mentis Life Sciences (OTC: NMLSF), Agile Therapeutics (NAS...
Extending the post-market rally Yesterday, the clinical-stage biotech Kezar Life Sciences (NASDAQ:KZR) has added ~92% in the early trading Tuesday as Wall Street reacts to the company’s mid-stage data for its lead asset zetomipzomib in active lupus nephritis (LN). LN, found i...
Clinical-stage biotech Kezar Life Sciences (NASDAQ:KZR) jumped ~83% in the post-market Monday after the company said that its experimental therapy for active lupus nephritis (LN) zetomipzomib showed a clinically meaningful renal response in a Phase 2 trial. The MISSION open label tr...
11 of 17 patients (64.7%) achieved an overall renal response of 50% or greater reduction in urine protein to creatinine ratio (UPCR) at 6 months 6 of 17 patients (35.2%) achieved a complete renal response, including a UPCR of 0.5 or less at 6 months Z...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Since June 15, Millennium Management’s Israel Englander has purchased stock in five companies . These companies are Franklin BSP Realty Trust (NYSE: FBRT ), VAALCO Energy (NYSE: EGY ), BioLife Solutio...
Gainers: bluebird (BLUE) +73%. Canopy Growth Corporation (CGC) +10%. Astra Space (ASTR) +5%. Adagio Therapeutics (ADGI) +5%. GDS Holdings Limited (GDS) +5%. Losers: RISE Education Cayman (REDU) -11%. Fulcrum Therapeutics (FULC) -7%. View (VIEW) -5%. Kezar Life Sciences (KZR) -...
Gainers: DBV Technologies (DBVT) +48%. Biodesix (BDSX) +15%. Intel Corporation (INTC) +7%. Limoneira (LMNR) +6%. Groupon (GRPN) +5%. Losers: Redbox Entertainment (RDBX) -5%. C4 Therapeutics (CCCC) -5%. Kezar Life Sciences (KZR) -5%. Iris Energy Limited (IREN) -5%. LumiraDx Lim...
Gainers:Sana Biotechnology (SANA) +9%. Fanhua (FANH) +8%. Sotera Health Company (SHC) +7%. ON Semiconductor Corporation (ON) +7%. MacroGenics (MGNX) +6%. Losers: Immunovant (IMVT) -7%. FTC Solar (FTCI) -7%. Biote (BTMD) -6%. Cue Health (HLTH) -5%. Kezar Life Sciences (KZR) -5...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks have never really managed to recreate the success they had in 2020 amid the Covid-19 outbreak. For a second year in running, the sector is caught in a rut, underperforming the beaten-down broader market. Th...
News, Short Squeeze, Breakout and More Instantly...
Kezar Life Sciences Inc. Company Name:
KZR Stock Symbol:
NASDAQ Market:
Kezar Life Sciences Inc. Website:
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate in a fireside chat at...
PALIZADE Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis actively enrolling; reiterating guidance of topline data in mid-2026 PORTOLA Phase 2a clinical trial of zetomipzomib in patients with autoimmune hepatitis actively enrolling; reiterating guidance of t...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...